Joel Picus
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
Papers in
- Oncology 109
- Cancer Immunotherapy and Biomarkers 21
- Pancreatic and Hepatic Oncology Research 21
- Colorectal Cancer Treatments and Studies 20
- Cancer Treatment and Pharmacology 17
-
- Prostate Cancer Treatment and Research 45
- Renal cell carcinoma treatment 27
- Co-authors
- Nicholas J. Vogelzang (25 shared papers)Susan Halabi (29 shared papers)Eric J. Small (23 shared papers)Jorge A. García (17 shared papers)Robert Dreicer (27 shared papers)Christopher J. Sweeney (15 shared papers)Neal J. Meropol (5 shared papers)Noah M. Hahn (19 shared papers)
- Journals
- Journal of Clinical Oncology (111 papers)Annals of Oncology (16 papers)Cancer (9 papers)The Journal of Urology (8 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Joel Picus
220 papers receiving 18.0k citations
Joel Picus's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 7.5k
- Pulmonary and Respiratory Medicine 7.7k
- Cancer Research 3.3k
- Immunology 2.0k
- Hepatology 618
Countries citing papers authored by Joel Picus
This map shows the geographic impact of Joel Picus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Picus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Picus more than expected).
Fields of papers citing papers by Joel Picus
This network shows the impact of papers produced by Joel Picus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Picus. The network helps show where Joel Picus may publish in the future.
Co-authors
The 25 scholars most cited alongside Joel Picus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 226 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Hit paper breakdown → | 2010 | 2352 |
| 2 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Hit paper breakdown → | 2015 | 1877 |
| 3 | Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1481 |
| 4 | Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Hit paper breakdown → | 2018 | 719 |
| 5 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 707 |
| 6 | Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Hit paper breakdown → | 1999 | 694 |
| 7 | Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) Hit paper breakdown → | 2010 | 681 |
| 8 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 512 |
| 9 | 2008 | 456 | |
| 10 | 1990 | 419 | |
| 11 | 2009 | 418 | |
| 12 | 2004 | 385 | |
| 13 | 2005 | 354 | |
| 14 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Hit paper breakdown → | 2016 | 317 |
| 15 | 1991 | 314 | |
| 16 | 2003 | 286 | |
| 17 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 272 |
| 18 | 2006 | 257 | |
| 19 | 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. | 2003 | 219 |
| 20 | 2010 | 210 |
About Joel Picus
Joel Picus is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Cancer Research, having authored 226 papers that have together received 18.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (45 papers), Bladder and Urothelial Cancer Treatments (28 papers), Renal cell carcinoma treatment (27 papers), Cancer Immunotherapy and Biomarkers (21 papers), Pancreatic and Hepatic Oncology Research (21 papers), Colorectal Cancer Treatments and Studies (20 papers), Cancer Treatment and Pharmacology (17 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (7.5k citations), Pulmonary and Respiratory Medicine (7.7k citations), Cancer Research (3.3k citations), Immunology (2.0k citations) and Hepatology (618 citations). Joel Picus has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Nicholas J. Vogelzang, Susan Halabi, Eric J. Small, Jorge A. García, Robert Dreicer, Christopher J. Sweeney, Neal J. Meropol, Noah M. Hahn, Gary A. Koretzky and Manish Kohli. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, The Journal of Urology and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.